30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Dermira Inc (DERM)

Track

Stock chart
Ticker: DERM Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Bald Eagle Acquisition Corp
1 purchase — total 767,362,969 USD
Buy 20 Feb 2020
Value US$3,735,787.85 | Price 33.60 | Shares 1,824
Planned sale 24 Dec 2019
Value US$2,324,750.65 | Price 298.96 | Shares 47,674
Planned sale 12 Dec 2019
Value US$36,000.00 | Price 12.00 | Shares 3,000
Sale 12 Sep 2019
Value US$52,636.20 | Price 8.77 | Shares 6,000
Buy 19 Aug 2019
Value US$199,998.26 | Price 8.54 | Shares 23,419
Sale 19 Aug 2019
Value US$199,998.26 | Price 8.54 | Shares 23,419
Planned sale 8 Apr 2019
Value US$525,000.00 | Price 15.00 | Shares 35,000
Planned sale 19 Oct 2018
Value US$55,000.00 | Price 13.75 | Shares 4,000
Planned buy 9 Jul 2018
Value US$119,950.80 | Price 10.00 | Shares 12,000
Planned buy 2 Jul 2018
Value US$119,997.62 | Price 8.71 | Shares 13,780
Planned buy 25 Jun 2018
Value US$119,586.38 | Price 9.84 | Shares 12,150
Planned buy 18 Jun 2018
Value US$119,954.12 | Price 10.10 | Shares 11,875
Planned sale 2 Mar 2018
Value US$62,500.00 | Price 25.00 | Shares 2,500
Planned sale 1 Mar 2018
Value US$12,658.00 | Price 25.32 | Shares 500
Planned sale 1 Mar 2018
Value US$15,510.00 | Price 25.85 | Shares 600
Planned sale 1 Feb 2018
Value US$85,641.90 | Price 28.55 | Shares 3,000
Planned sale 1 Feb 2018
Value US$17,322.00 | Price 28.87 | Shares 600
Planned sale 2 Jan 2018
Value US$2,803.00 | Price 28.03 | Shares 100
Planned sale 2 Jan 2018
Value US$78,406.72 | Price 27.04 | Shares 2,900
Planned sale 2 Jan 2018
Value US$16,818.00 | Price 28.03 | Shares 600
Planned sale 2 Jan 2018
Value US$5,581.00 | Price 27.91 | Shares 200
Planned sale 2 Jan 2018
Value US$493,773.00 | Price 27.04 | Shares 18,258
Planned sale 18 Dec 2017
Value US$82,010.70 | Price 27.34 | Shares 3,000
Planned sale 13 Dec 2017
Value US$137,565.50 | Price 27.51 | Shares 5,000
Planned sale 1 Dec 2017
Value US$15,294.00 | Price 25.49 | Shares 600
Planned sale 2 Nov 2017
Value US$137,608.00 | Price 27.52 | Shares 5,000
Planned sale 1 Nov 2017
Value US$16,092.00 | Price 26.82 | Shares 600
Planned sale 11 Oct 2017
Value US$225,300.00 | Price 30.04 | Shares 7,500
Planned sale 10 Oct 2017
Value US$137,606.00 | Price 27.52 | Shares 5,000
Planned sale 2 Oct 2017
Value US$16,194.00 | Price 26.99 | Shares 600
Planned sale 18 Sep 2017
Value US$261,335.50 | Price 27.51 | Shares 9,500
Planned sale 1 Sep 2017
Value US$14,136.00 | Price 23.56 | Shares 600
Planned sale 28 Aug 2017
Value US$14,286.00 | Price 23.81 | Shares 600
Buy 14 Aug 2017
Value US$239,460.00 | Price 23.95 | Shares 10,000
Buy 10 Aug 2017
Value US$451,470.00 | Price 22.57 | Shares 20,000
Planned sale 1 Aug 2017
Value US$13,790.70 | Price 27.58 | Shares 500
Planned sale 5 Jul 2017
Value US$75,007.50 | Price 30.00 | Shares 2,500
Planned sale 3 Jul 2017
Value US$145,297.50 | Price 29.06 | Shares 5,000
Planned sale 20 Jun 2017
Value US$75,032.00 | Price 30.01 | Shares 2,500
Planned sale 2 Jun 2017
Value US$30,950.81 | Price 27.61 | Shares 1,121
Planned sale 1 Jun 2017
Value US$106,672.50 | Price 27.50 | Shares 3,879
Planned sale 15 May 2017
Value US$35,515.84 | Price 27.07 | Shares 1,312
Planned sale 1 May 2017
Value US$84,115.75 | Price 33.65 | Shares 2,500
Planned sale 1 May 2017
Value US$3,439.00 | Price 34.39 | Shares 100
Planned sale 1 May 2017
Value US$265,832.63 | Price 33.65 | Shares 7,900
Planned sale 1 May 2017
Value US$17,030.00 | Price 34.06 | Shares 500
Planned sale 17 Apr 2017
Value US$44,266.82 | Price 33.97 | Shares 1,303
Planned sale 3 Apr 2017
Value US$17,015.00 | Price 34.03 | Shares 500
Planned sale 3 Apr 2017
Value US$48,118.00 | Price 34.03 | Shares 1,414
Planned sale 3 Apr 2017
Value US$219,831.46 | Price 33.38 | Shares 6,586
Planned sale 3 Apr 2017
Value US$17,730.10 | Price 34.03 | Shares 521
Planned sale 3 Apr 2017
Value US$66,106.32 | Price 33.40 | Shares 1,979
Planned sale 15 Mar 2017
Value US$3,637.00 | Price 36.37 | Shares 100
Planned sale 15 Mar 2017
Value US$42,993.05 | Price 35.74 | Shares 1,203
Planned sale 3 Mar 2017
Value US$150,415.60 | Price 37.60 | Shares 4,000
Planned sale 1 Mar 2017
Value US$17,547.00 | Price 35.09 | Shares 500
Planned sale 1 Mar 2017
Value US$3,589.00 | Price 35.89 | Shares 100
Planned sale 1 Mar 2017
Value US$13,795.00 | Price 34.49 | Shares 400
Planned sale 1 Mar 2017
Value US$40,569.00 | Price 33.81 | Shares 1,200
Planned sale 1 Mar 2017
Value US$26,079.04 | Price 32.60 | Shares 800
Planned sale 1 Mar 2017
Value US$9,768.69 | Price 35.91 | Shares 272
Planned sale 1 Mar 2017
Value US$21,046.98 | Price 35.08 | Shares 600
Planned sale 1 Mar 2017
Value US$146,782.39 | Price 33.91 | Shares 4,328
Planned sale 1 Mar 2017
Value US$191,347.22 | Price 32.99 | Shares 5,800
Planned sale 15 Feb 2017
Value US$12,646.10 | Price 31.38 | Shares 403
Planned sale 15 Feb 2017
Value US$27,471.51 | Price 30.52 | Shares 900
Planned sale 15 Feb 2017
Value US$16,000.00 | Price 32.00 | Shares 500
Planned sale 14 Feb 2017
Value US$45,153.01 | Price 30.00 | Shares 1,505
Planned sale 1 Feb 2017
Value US$6,117.88 | Price 29.99 | Shares 204
Planned sale 1 Feb 2017
Value US$140,646.54 | Price 29.33 | Shares 4,796
Planned sale 1 Feb 2017
Value US$29,851.89 | Price 30.00 | Shares 995
Planned sale 17 Jan 2017
Value US$6,016.00 | Price 30.08 | Shares 200
Planned sale 17 Jan 2017
Value US$31,920.82 | Price 28.94 | Shares 1,103
Planned sale 4 Jan 2017
Value US$97,543.20 | Price 32.51 | Shares 3,000
Planned sale 4 Jan 2017
Value US$16,000.00 | Price 32.00 | Shares 500
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2020-02-20 2020-02-20 B Purchase
Bald Eagle Acquisition Corp
Large shareholder
1,824 -28.7%
33.60
US$3,735,788 		1,824 -28.7% 33.60 US$3,735,788
2019-12-26 2019-12-24 PlS Planned sale Fust Matthew K
47,674 +13.9%
298.96
US$2,324,751 		47,674 +13.9% 298.96 US$2,324,751
2019-12-13 2019-12-12 PlS Planned sale Fust Matthew K
74,825 +45.4%
286.28
US$2,630,732 		74,825 +45.4% 286.28 US$2,630,732
2019-09-16 2019-09-12 S Sale
3.8
Fust Matthew K
6,000 -35.2%
8.77
US$52,636 		6,000 -35.2% 8.77 US$52,636
2019-08-19 2019-08-19 B Purchase WIGGANS THOMAS G

CEO & Chairman of the Board
23,419 +44.6%
8.54
US$199,998 		23,419 +44.6% 8.54 US$199,998
2019-08-19 2019-08-19 S Sale Pena Luis C.

Chief Development Officer
23,419 -57.6%
8.54
US$199,998 		23,419 -57.6% 8.54 US$199,998
2019-04-09 2019-04-08 PlS Planned sale
BAUER EUGENE A

Chief Medical Officer
35,000 -79.7%
15.00
US$525,000 		35,000 -79.7% 15.00 US$525,000
2018-10-19 2018-10-19 PlS Planned sale Fust Matthew K
4,000 -22.2%
13.75
US$55,000 		4,000 -22.2% 13.75 US$55,000
2018-07-09 2018-07-09 PP Planned purchase WIGGANS THOMAS G

CEO & Chairman of the Board
12,000 +17.8%
10.00
US$119,951 		12,000 +17.8% 10.00 US$119,951
2018-07-02 2018-07-02 PP Planned purchase WIGGANS THOMAS G

CEO & Chairman of the Board
13,780 +25.6%
8.71
US$119,998 		13,780 +25.6% 8.71 US$119,998
2018-06-25 2018-06-25 PP Planned purchase WIGGANS THOMAS G

CEO & Chairman of the Board
12,150 +29.2%
9.84
US$119,586 		12,150 +29.2% 9.84 US$119,586
2018-06-18 2018-06-18 PP Planned purchase WIGGANS THOMAS G

CEO & Chairman of the Board
11,875 +40.0%
10.10
US$119,954 		11,875 +40.0% 10.10 US$119,954
2018-03-06 2018-03-02 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
2,500 -47.2%
25.00
US$62,500 		2,500 -47.2% 25.00 US$62,500
2018-03-02 2018-03-01 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
500 -15.1%
25.32
US$12,658 		500 -15.1% 25.32 US$12,658
2018-03-02 2018-03-01 PlS Planned sale Cohen David E
600 -2.0%
25.85
US$15,510 		600 -2.0% 25.85 US$15,510
2018-02-02 2018-02-01 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
3,000 -51.7%
28.55
US$85,642 		3,000 -51.7% 28.55 US$85,642
2018-02-02 2018-02-01 PlS Planned sale Cohen David E
600 -1.9%
28.87
US$17,322 		600 -1.9% 28.87 US$17,322
2018-01-04 2018-01-02 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
100 -3.4%
28.03
US$2,803 		100 -3.4% 28.03 US$2,803
2018-01-04 2018-01-02 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
2,900 -50.0%
27.04
US$78,407 		2,900 -50.0% 27.04 US$78,407
2018-01-04 2018-01-02 PlS Planned sale Cohen David E
600 -1.9%
28.03
US$16,818 		600 -1.9% 28.03 US$16,818
2018-01-04 2018-01-02 PlS Planned sale Griffith Christopher M.

SVP Head Corp. Dev. & Strategy
200 -0.5%
27.91
US$5,581 		200 -0.5% 27.91 US$5,581
2018-01-04 2018-01-02 PlS Planned sale Griffith Christopher M.

SVP Head Corp. Dev. & Strategy
18,258 -29.6%
27.04
US$493,773 		18,258 -29.6% 27.04 US$493,773
2017-12-20 2017-12-18 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
3,000 -43.9%
27.34
US$82,011 		3,000 -43.9% 27.34 US$82,011
2017-12-15 2017-12-13 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
5,000 -26.8%
27.51
US$137,566 		5,000 -26.8% 27.51 US$137,566
2017-12-05 2017-12-01 PlS Planned sale Cohen David E
600 -1.9%
25.49
US$15,294 		600 -1.9% 25.49 US$15,294
2017-11-03 2017-11-02 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
5,000 -27.1%
27.52
US$137,608 		5,000 -27.1% 27.52 US$137,608
2017-11-03 2017-11-01 PlS Planned sale Cohen David E
600 -1.8%
26.82
US$16,092 		600 -1.8% 26.82 US$16,092
2017-10-13 2017-10-11 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
7,500 -21.8%
30.04
US$225,300 		7,500 -21.8% 30.04 US$225,300
2017-10-11 2017-10-10 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
5,000 -27.1%
27.52
US$137,606 		5,000 -27.1% 27.52 US$137,606
2017-10-03 2017-10-02 PlS Planned sale Cohen David E
600 -1.8%
26.99
US$16,194 		600 -1.8% 26.99 US$16,194
2017-09-19 2017-09-18 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
9,500 -41.4%
27.51
US$261,336 		9,500 -41.4% 27.51 US$261,336
2017-09-05 2017-09-01 PlS Planned sale Cohen David E
600 -1.8%
23.56
US$14,136 		600 -1.8% 23.56 US$14,136
2017-08-29 2017-08-28 PlS Planned sale Cohen David E
600 -1.7%
23.81
US$14,286 		600 -1.7% 23.81 US$14,286
2017-08-14 2017-08-14 B Purchase CRAVES FRED B
10,000 +50.0%
23.95
US$239,460 		10,000 +50.0% 23.95 US$239,460
2017-08-14 2017-08-10 B Purchase CRAVES FRED B
20,000 +inf%
22.57
US$451,470 		20,000 +inf% 22.57 US$451,470
2017-08-02 2017-08-01 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
500 -6.1%
27.58
US$13,791 		500 -6.1% 27.58 US$13,791
2017-07-06 2017-07-05 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
2,500 -6.8%
30.00
US$75,008 		2,500 -6.8% 30.00 US$75,008
2017-07-05 2017-07-03 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
5,000 -39.4%
29.06
US$145,298 		5,000 -39.4% 29.06 US$145,298
2017-06-21 2017-06-20 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
2,500 -6.3%
30.01
US$75,032 		2,500 -6.3% 30.01 US$75,032
2017-06-05 2017-06-02 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
1,121 -12.7%
27.61
US$30,951 		1,121 -12.7% 27.61 US$30,951
2017-06-05 2017-06-01 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
3,879 -33.5%
27.50
US$106,672 		3,879 -33.5% 27.50 US$106,672
2017-05-16 2017-05-15 PlS Planned sale Griffith Christopher M.

SVP Head Corp. Dev. & Strategy
1,312 -2.8%
27.07
US$35,516 		1,312 -2.8% 27.07 US$35,516
2017-05-03 2017-05-01 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
2,500 -6.0%
33.65
US$84,116 		2,500 -6.0% 33.65 US$84,116
2017-05-03 2017-05-01 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
100 -1.5%
34.39
US$3,439 		100 -1.5% 34.39 US$3,439
2017-05-03 2017-05-01 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
7,900 -54.6%
33.65
US$265,833 		7,900 -54.6% 33.65 US$265,833
2017-05-03 2017-05-01 PlS Planned sale RINGO WILLIAM R
500 -100.0%
34.06
US$17,030 		500 -100.0% 34.06 US$17,030
2017-04-18 2017-04-17 PlS Planned sale Griffith Christopher M.

SVP Head Corp. Dev. & Strategy
1,303 -2.8%
33.97
US$44,267 		1,303 -2.8% 33.97 US$44,267
2017-04-04 2017-04-03 PlS Planned sale RINGO WILLIAM R
500 -100.0%
34.03
US$17,015 		500 -100.0% 34.03 US$17,015
2017-04-04 2017-04-03 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
1,414 -17.9%
34.03
US$48,118 		1,414 -17.9% 34.03 US$48,118
2017-04-04 2017-04-03 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
6,586 -45.5%
33.38
US$219,831 		6,586 -45.5% 33.38 US$219,831
2017-04-04 2017-04-03 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
521 -1.2%
34.03
US$17,730 		521 -1.2% 34.03 US$17,730
2017-04-04 2017-04-03 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
1,979 -4.4%
33.40
US$66,106 		1,979 -4.4% 33.40 US$66,106
2017-03-16 2017-03-15 PlS Planned sale Griffith Christopher M.

SVP Head Corp. Dev. & Strategy
100 -0.2%
36.37
US$3,637 		100 -0.2% 36.37 US$3,637
2017-03-16 2017-03-15 PlS Planned sale Griffith Christopher M.

SVP Head Corp. Dev. & Strategy
1,203 -2.6%
35.74
US$42,993 		1,203 -2.6% 35.74 US$42,993
2017-03-07 2017-03-03 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
4,000 -38.2%
37.60
US$150,416 		4,000 -38.2% 37.60 US$150,416
2017-03-02 2017-03-01 PlS Planned sale RINGO WILLIAM R
500 -100.0%
35.09
US$17,547 		500 -100.0% 35.09 US$17,547
2017-03-02 2017-03-01 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
100 -0.2%
35.89
US$3,589 		100 -0.2% 35.89 US$3,589
2017-03-02 2017-03-01 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
400 -0.9%
34.49
US$13,795 		400 -0.9% 34.49 US$13,795
2017-03-02 2017-03-01 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
1,200 -2.6%
33.81
US$40,569 		1,200 -2.6% 33.81 US$40,569
2017-03-02 2017-03-01 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
800 -1.7%
32.60
US$26,079 		800 -1.7% 32.60 US$26,079
2017-03-02 2017-03-01 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
272 -4.0%
35.91
US$9,769 		272 -4.0% 35.91 US$9,769
2017-03-02 2017-03-01 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
600 -8.2%
35.08
US$21,047 		600 -8.2% 35.08 US$21,047
2017-03-02 2017-03-01 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
4,328 -37.1%
33.91
US$146,782 		4,328 -37.1% 33.91 US$146,782
2017-03-02 2017-03-01 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
5,800 -33.2%
32.99
US$191,347 		5,800 -33.2% 32.99 US$191,347
2017-02-16 2017-02-15 PlS Planned sale Griffith Christopher M.

SVP Head Corp. Dev. & Strategy
403 -0.9%
31.38
US$12,646 		403 -0.9% 31.38 US$12,646
2017-02-16 2017-02-15 PlS Planned sale Griffith Christopher M.

SVP Head Corp. Dev. & Strategy
900 -1.9%
30.52
US$27,472 		900 -1.9% 30.52 US$27,472
2017-02-16 2017-02-15 PlS Planned sale RINGO WILLIAM R
500 -100.0%
32.00
US$16,000 		500 -100.0% 32.00 US$16,000
2017-02-15 2017-02-14 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
1,505 -3.1%
30.00
US$45,153 		1,505 -3.1% 30.00 US$45,153
2017-02-03 2017-02-01 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
204 -3.1%
29.99
US$6,118 		204 -3.1% 29.99 US$6,118
2017-02-03 2017-02-01 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
4,796 -41.8%
29.33
US$140,647 		4,796 -41.8% 29.33 US$140,647
2017-02-02 2017-02-01 PlS Planned sale BAUER EUGENE A

Chief Medical Officer
995 -2.0%
30.00
US$29,852 		995 -2.0% 30.00 US$29,852
2017-01-19 2017-01-17 PlS Planned sale Griffith Christopher M.

VP Corp. Dev. & Strategy
200 -0.4%
30.08
US$6,016 		200 -0.4% 30.08 US$6,016
2017-01-19 2017-01-17 PlS Planned sale Griffith Christopher M.

VP Corp. Dev. & Strategy
1,103 -2.4%
28.94
US$31,921 		1,103 -2.4% 28.94 US$31,921
2017-01-05 2017-01-04 PlS Planned sale WIGGANS THOMAS G

CEO & Chairman of the Board
3,000 -31.7%
32.51
US$97,543 		3,000 -31.7% 32.51 US$97,543
2017-01-04 2017-01-04 PlS Planned sale RINGO WILLIAM R
500 -100.0%
32.00
US$16,000 		500 -100.0% 32.00 US$16,000
Explore more

More insider trading research around Dermira Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America